Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 36K
2: EX-99.1 Miscellaneous Exhibit HTML 54K
6: R1 Document and Entity Information Document HTML 47K
9: XML IDEA XML File -- Filing Summary XML 11K
7: XML XBRL Instance -- tvst-20220907_htm XML 22K
8: EXCEL IDEA Workbook of Financial Reports XLSX 8K
4: EX-101.LAB XBRL Labels -- tvst-20220907_lab XML 69K
5: EX-101.PRE XBRL Presentations -- tvst-20220907_pre XML 34K
3: EX-101.SCH XBRL Schema -- tvst-20220907 XSD 10K
10: JSON XBRL Instance as JSON Data -- MetaLinks 12± 18K
11: ZIP XBRL Zipped Folder -- 0001860782-22-000050-xbrl Zip 28K
Registrant’s telephone number, including area code: (i339) i499-9300
Not
Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
i☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading Symbol(s)
Name of each exchange on which registered
iCommon Stock, $0.0001 par value per share
iTSVT
iThe
NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ix
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. io
Item
8.01Other Events.
On September 7, 2022, 2seventy bio, Inc. announced plans to initiate the KarMMa-9 study to evaluate ABECMA (idecabtagene vicleucel) in newly diagnosed multiple myeloma patients who have suboptimal response to transplant.A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Cover
Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)
____________
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
